|
|
Article: FDA adds black box to Xolair.(Warnings/Recalls)(Brief article)
- Article from:
- Adverse Event Reporting News
- Article date:
- July 16, 2007
CopyrightCOPYRIGHT 2007 Washington Information Source, Inc. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
FDA finalized a strong new label warning patients and doctors about a potentially deadly allergic reaction from Genentech's asthma drug Xolair.
The agency had proposed the so-called black box warning about anaphylaxis in February, but announced final wording of the label on July 2.
Xolair, given as an injection and known generically as omalizumab, is approved to treat adults and adolescents 12 years of age and older for moderate to severe asthma.
The previous label warned that ...